Burkholderia infections are caused by a group of viruses that are common in the animal kingdom. They include the herpes simplex virus (HSV), the Epstein-Barr virus (EBV), and the cytomegalovirus (CMD). These viruses often attack the skin, eyes, and respiratory systems, causing fever, skin rash, diarrhea, and other problems. The name ‘burkholderia’ comes from the word burk, an archaic word for cattle.
Apply Here For The Sample Copy Of The Report: https://www.coherentmarketinsights.com/insight/request-sample/153
Competitive Landscape:
iQur Ltd, NanoBio Corporation, Novabiotics Ltd, Aridis Pharmaceuticals LLC, SUN pharma and others.
Key Market Drivers:
The increasing prevalence of lung disease around the globe is driving growth of the Burkholderia infections market. According to the World Health Organization, About 65 million people suffer from the chronic obstructive pulmonary disease (COPD), and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. Thus growing cases of respiratory disease is fueling growth of the market.
Growing research and developments programs in the field is fostering growth of the market. For instance, in January 2020, The Cystic Fibrosis (CF) Foundation awarded nearly $700,000 contract to Calibr, the drug discovery, and development arm of Scripps Research, to support projects aiming to identify compounds that could treat infections caused by Burkholderia cepacia complex. The contract will provide funding for two years and is valued at $692,000
Covid-19 Impact Analysis
The COVID -19 has spread to almost every country around the world and World Health Organization has declared it a public health emergency. The global impacts of the coronavirus disease 2019 has a significant impact on the Burkholderia Infections market in 2020. The market was positively impacted as there was a rise in the cases of covid-19 patients with lung disease and weak immune systems.
Key Takeaways:
- The Burkholderia infections market is expected to exhibit a CAGR of XX % over the forecast period, owing to the continuous launch of a new drug with high efficacy. For instance, in October 2018, Synspira, a company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, announced that it has been granted Orphan Designation by the United States Food and Drug Administration (FDA) for poly (acetyl, arginyl) glucosamine (PAAG15A), for the treatment of cystic fibrosis.
- North America is expected to hold a dominant position in the global Burkholderia infections market and this is attributed to the high prevalence of lung disease in the region. The National Center for Health Statistics reports that the prevalence of physician ambulatory-care visits for respiratory diseases is highest in persons aged >85 years and is 57% and 85% lower in those aged 75 to 84 years and 65 to 74 years, respectively.
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/153
About US
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]